NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1.

纽约--（商业新闻短讯）--Schrödinger（纳斯达克：SDGR）今天在第36届EORTC-NCI-AACR研讨会（ENA 2024）的海报会议上宣布了其研究性Wee1/Myt1抑制剂SGR-3515的新临床前数据。数据表明，在临床前模型中，与仅靶向Wee1或Myt1的抑制剂相比，用SGR-3515治疗可产生协同抗肿瘤活性，从而导致更深更持久的反应。

The preclinical data also show that SGR-3515 has a favorable pharmacological profile and dosing schedule that supports evaluating intermittent dosing in patients..

临床前数据还表明，SGR-3515具有良好的药理学特征和给药方案，可支持评估患者的间歇性给药。。

Wee1 and Myt1 kinases regulate the cell cycle and DNA damage response, allowing time for DNA repair before cell division takes place. Concurrent loss of function or inhibition of Wee1 and Myt1 confers selective vulnerability in cancer cells, a mechanism referred to as synthetic lethality, which has become an emerging therapeutic strategy for a range of cancers.

Wee1和Myt1激酶调节细胞周期和DNA损伤反应，在细胞分裂发生之前有时间进行DNA修复。Wee1和Myt1的同时功能丧失或抑制赋予癌细胞选择性脆弱性，这种机制被称为合成致死性，已成为一系列癌症的新兴治疗策略。

A Phase 1 dose-escalation study of SGR-3515 in patients with advanced solid tumors is ongoing in the U.S. and Canada, and initial data from the clinical study is expected in the second half of 2025..

美国和加拿大正在进行SGR-3515在晚期实体瘤患者中的第一阶段剂量递增研究，临床研究的初步数据预计将在2025年下半年公布。。

Schrödinger will also present preclinical data from its PRMT5-MTA program during a poster session on October 25. Schrödinger scientists have identified a novel series of selective, potent PRMT5-MTA inhibitors and are optimizing lead compounds for use in peripheral and brain tumors.

Schrödinger还将在10月25日的海报会议上展示其PRMT5-MTA计划的临床前数据。薛定谔（Schrödinger）的科学家已经确定了一系列新的选择性，有效的PRMT5-MTA抑制剂，并正在优化用于外周和脑肿瘤的先导化合物。

“We are pleased to share these encouraging preclinical data on SGR-3515, a potential best-in-class treatment for patients with a broad range of solid tumors, including uterine and ovarian cancers, two patient populations with high unmet need,” stated Karen Akinsanya, Ph.D., president of R&D therapeutics at Schrödinger.

Schrödinger研发治疗总裁Karen Akinsanya博士表示：“我们很高兴分享SGR-3515的这些令人鼓舞的临床前数据，SGR-3515是一种潜在的同类最佳治疗方法，适用于包括子宫癌和卵巢癌在内的多种实体瘤患者，这两种患者群体的需求尚未得到满足。”。

“We also look forward to presenting preclinical data on the discovery of a novel series of compounds for our PRMT5-MTA inhibitor program. These programs highlight how we are deploying our computational platform at scale to discover highly optimized molecules to address diseases with significant medical need, and we believe the future of our therapeutics portfolio is very promising.”.

“我们还期待着为我们的PRMT5-MTA抑制剂计划提供一系列新化合物的临床前数据。这些计划强调了我们如何大规模部署我们的计算平台，以发现高度优化的分子，以解决具有重大医疗需求的疾病，我们相信我们治疗组合的未来非常有前景。”。

SGR-3515 Data at ENA 2024

SGR-3515 2024年ENA数据

The presentation (Abstract # 147), “Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models,” includes preclinical data demonstrating superior anti-tumor activity of SGR-3515 compared to inhibitors of Wee1 or Myt1 alone due to strong target engagement of both Wee1 and Myt1.

该报告（摘要147）“发现SGR-3515是一种在异种移植肿瘤模型中具有不同药理学特性的一流Wee1/Myt1抑制剂”，包括临床前数据，证明SGR-3515与Wee1抑制剂相比具有优异的抗肿瘤活性。由于Wee1和Myt1的强烈靶向参与，单独使用Myt1。

The data show that SGR-3515 is a more potent co-inhibitor of both Wee1 and Myt1 than previously disclosed inhibitors of either target. These data are consistent with prior preclinical observations demonstrating that SGR-3515 has a unique and differentiated pharmacological profile that supports evaluating an intermittent dosing schedule of three days on and 11 days off, as well as five days on and nine days off, which maintained anti-tumor activity while allowing recovery from any mechanism-based hematological toxicity in preclinical models..

数据显示，SGR-3515是Wee1和Myt1的一种比先前公开的任一靶标抑制剂更有效的共抑制剂。。。

The preclinical data also demonstrate superior kinase selectivity and in vitro cell potency of SGR-3515 across a broad cell line panel compared to other known Wee1 and Myt1 inhibitors. These new data suggest that SGR-3515 is significantly more selective than existing compounds with low potential for drug-drug interaction..

与其他已知的Wee1和Myt1抑制剂相比，临床前数据还表明SGR-3515在广泛的细胞系组中具有优异的激酶选择性和体外细胞效力。这些新数据表明，SGR-3515比现有的药物相互作用潜力低的化合物具有更高的选择性。。

PRMT5-MTA Data at ENA 2024

2024年ENA上的PRMT5-MTA数据

Additionally, Schrödinger will present new preclinical data on its PRMT5-MTA inhibitor program at a poster session during the meeting on October 25 from 9:00 a.m. - 3:00 p.m. CEST. The presentation (Abstract # 372), “Discovery of a highly MTA-synergistic series of PRMT5 inhibitors for the treatment of MTAP-deficient tumors by virtual screening technology,” will include preclinical data on the discovery of highly selective PRMT5-MTA inhibitors.

此外，Schrödinger将在10月25日上午9:00至下午3:00 CEST会议期间的海报会议上介绍其PRMT5-MTA抑制剂计划的新临床前数据。演讲（摘要#372），“通过虚拟筛选技术发现用于治疗MTAP缺陷型肿瘤的高度MTA协同系列PRMT5抑制剂”，将包括关于发现高选择性PRMT5-MTA抑制剂的临床前数据。

The poster will describe how Schrödinger’s virtual screening platform facilitated the identification of structurally distinct chemical matter with a high degree of MTA-synergy for compounds within a novel chemical series in vitro and in cellular contexts. Schrödinger has identified a novel series of selective, potent PRMT5-MTA inhibitors that did not show major off-target liabilities such as hERG inhibition in preclinical studies and may be suitable for use in combinations across tumor types..

海报将描述薛定谔的虚拟筛选平台如何在体外和细胞环境中促进结构独特的化学物质的鉴定，并对新型化学系列中的化合物具有高度的MTA协同作用。Schrödinger已经确定了一系列新的选择性，有效的PRMT5-MTA抑制剂，这些抑制剂在临床前研究中没有显示出主要的脱靶责任，例如hERG抑制，并且可能适用于多种肿瘤类型的组合。。

About Schrödinger

关于薛定谔

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods.

薛定谔正在改变治疗方法和材料的发现方式。薛定谔开创了一个基于物理的计算平台，与传统方法相比，该平台能够更快，更低成本地发现用于药物开发和材料应用的高质量新型分子。

The computational platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs..

该计算平台由世界各地的生物制药和工业公司、学术机构和政府实验室授权。薛定谔的多学科药物发现团队还利用该软件平台推进了一系列合作和专有计划，以解决未满足的医疗需求。。

Founded in 1990, Schrödinger has approximately 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com.

薛定谔公司成立于1990年，拥有大约850名员工，在70多个国家与客户和合作者合作。要了解更多信息，请访问www.schrodinger.com，在LinkedIn上关注我们，或访问我们的博客extractions.com。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的警示说明

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including but not limited to those statements regarding the potential advantages of our computational platform, the potential of Wee1/Myt1 and PRMT5-MTA inhibition for the treatment of cancers, the therapeutic potential and characteristics of SGR-3515 and the PRMT5-MTA inhibitors we have identified, the expected timing and design of our Phase 1 clinical trial of SGR-3515, including the plan to evaluate SGR-3515 with an intermittent dosing schedule, and the future potential of our therapeutics portfolio.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明，包括但不限于关于我们的计算平台的潜在优势，Wee1/Myt1和PRMT5-MTA抑制治疗癌症的潜力，SGR-3515和PRMT5-MTA抑制剂的治疗潜力和特征，我们已经确定的SGR-3515第一阶段临床试验的预期时间和设计，包括评估SGR-3515间歇给药方案的计划，以及我们治疗组合的未来潜力。

Statements including words such as “aim,” 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' “goal,” 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and statements in the future tense are forward-looking statements.

包括“目标”、“预期”、“相信”、“沉思”、“继续”、“可能”、“估计”、“预期”、“目标”、“打算”、“可能”、“可能”、“计划”、“潜力”、“预测”、“项目”、“应该”、“目标”、“意志”、“将会”等词语在内的陈述以及未来时态的陈述都是前瞻性陈述。

These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including the uncertainties inherent in drug development, such as the conduct of research activities and the timing of and our ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies and early clinical trials will be predictive of results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of clinical trials and application.

。实际结果可能与前瞻性声明中描述的结果有很大差异，并且受到我们无法控制的各种假设，不确定性，风险和因素的影响，包括药物开发固有的不确定性，例如研究活动的开展以及我们启动和完成临床前研究和临床试验的时间和能力，临床前研究和早期临床试验的结果是否可以预测后期临床前研究和临床试验的结果，与临床试验和应用的监管审查相关的不确定性。